Time to onset of cannabidiol (CBD) treatment effect in Lennox-Gastaut syndrome: Analysis from two randomized controlled trials

被引:26
|
作者
Privitera, Michael [1 ]
Bhathal, Hari [2 ]
Wong, Matthew [3 ]
Cross, J. Helen [4 ]
Wirrell, Elaine [5 ]
Marsh, Eric D. [6 ]
Mazurkiewicz-Beldzinska, Maria [7 ]
Villanueva, Vicente [8 ]
Checketts, Daniel [9 ]
Knappertz, Volker [10 ]
VanLandingham, Kevan [10 ]
机构
[1] Univ Cincinnati, Med Ctr, Cincinnati, OH 45267 USA
[2] Neuroctr Barcelona, Teknon Med Ctr, Barcelona, Spain
[3] Wake Forest Baptist Med Ctr, Winston Salem, NC USA
[4] UCL, Great Ormond St Inst Child Hlth, Natl Inst Hlth Res, Biomed Res Ctr, London, England
[5] Mayo Clin, Rochester, MN USA
[6] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA
[7] Med Univ Gdansk, Gdansk, Poland
[8] Univ & Polytech Hosp La Fe, Valencia, Spain
[9] GW Res Ltd, Cambridge, England
[10] Greenwich Biosci Inc, Carlsbad, CA USA
关键词
antiepileptic drug; antiseizure medication; childhood onset epilepsy; drop seizures; treatment‐ resistant epilepsy;
D O I
10.1111/epi.16878
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective To estimate time to onset of cannabidiol (CBD) treatment effect (seizure reduction and adverse events [AEs]), we conducted post hoc analyses of data from two randomized, placebo-controlled, Phase 3 trials, GWPCARE3 (NCT02224560) and GWPCARE4 (NCT02224690), of patients with Lennox-Gastaut syndrome. Methods Patients received plant-derived pharmaceutical formulation of highly purified CBD (Epidiolex, 100 mg/ml oral solution) at 10 mg/kg/day (CBD10; GWPCARE3) or 20 mg/kg/day (CBD20; both trials) or placebo for 14 weeks. Treatment started at 2.5 mg/kg/day for all groups and reached 10 mg/kg/day on Day 7 and 20 mg/kg/day (CBD20 and matching placebo only) on Day 11. Percentage change from baseline in drop seizure frequency was calculated by cumulative day (i.e., including all previous days). Time to onset and resolution of AEs were evaluated. Results Overall, 235 patients received CBD (CBD10 [GWPCARE3 only], n = 67; CBD20 [pooled GWPCARE3&4], n = 168) and 161 received placebo. Mean (range) age was 15.3 years (2.6-48.0). Patients had previously discontinued a median (range) of six (0-28) antiepileptic drugs (AEDs) and were currently taking a median of three (0-5) AEDs. Differences in drop seizure reduction between placebo and CBD emerged during the titration period and became nominally significant by Day 6 (p = .008) for pooled CBD treatment groups. Separation between placebo and CBD in >= 50% responder rate emerged by Day 6. Onset of the first reported AE occurred during the titration period in 45% of patients (CBD10, 46%; CBD20, 52%; placebo, 38%). In patients with AEs, resolution occurred within 4 weeks of onset in 53% of placebo and 39% of CBD patients and by end of study in 63% of placebo and 61% of CBD patients. Significance Treatment effect (efficacy and AEs) of CBD may occur within 1 week of starting treatment. Although AEs lasted longer for CBD than placebo, most resolved within the 14-week period.
引用
收藏
页码:1130 / 1140
页数:11
相关论文
共 50 条
  • [41] Cost-Effectiveness of Cannabidiol Adjunct Therapy versus Usual Care for the Treatment of Seizures in Lennox-Gastaut Syndrome
    Edward E. Neuberger
    Josh J. Carlson
    David L. Veenstra
    PharmacoEconomics, 2020, 38 : 1237 - 1245
  • [42] Cost-Effectiveness of Cannabidiol Adjunct Therapy versus Usual Care for the Treatment of Seizures in Lennox-Gastaut Syndrome
    Neuberger, Edward E.
    Carlson, Josh J.
    Veenstra, David L.
    PHARMACOECONOMICS, 2020, 38 (11) : 1237 - 1245
  • [43] Efficacy and Safety of Fenfluramine for the Treatment of Seizures Associated With Lennox-Gastaut Syndrome A Randomized Clinical Trial
    Knupp, Kelly G.
    Scheffer, Ingrid E.
    Ceulemans, Berten
    Sullivan, Joseph E.
    Nickels, Katherine C.
    Lagae, Lieven
    Guerrini, Renzo
    Zuberi, Sameer M.
    Nabbout, Rima
    Riney, Kate
    Shore, Svetlana
    Agarwal, Anupam
    Lock, Michael
    Farfel, Gail M.
    Galer, Bradley S.
    Gammaitoni, Arnold R.
    Davis, Ronald
    Gil-Nagel, Antonio
    JAMA NEUROLOGY, 2022, 79 (06) : 554 - 564
  • [44] Functional brain network analysis using electroencephalography in late-onset Lennox-Gastaut syndrome
    Wang, Zhi Ji
    Park, Soyoung
    Kim, Heung Dong
    Kang, Hoon-Chul
    Kim, Nam-Young
    Hur, Yun Jung
    EPILEPSY RESEARCH, 2024, 203
  • [45] Withdrawal-related adverse events from clinical trials of clobazam in Lennox-Gastaut syndrome
    Tolbert, Dwain
    Harris, Stuart I.
    Bekersky, Ihor
    Lee, Deborah
    Isojarvi, Jouko
    EPILEPSY & BEHAVIOR, 2014, 37 : 11 - 15
  • [46] RUFINAMIDE AS ADJUNCTIVE TREATMENT FOR ADULTS WITH LENNOX-GASTAUT SYNDROME: SUBGROUP ANALYSIS FROM A PHASE III TRIAL
    Striano, P.
    McMurray, R.
    EPILEPSIA, 2015, 56 : 211 - 211
  • [47] Cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox-Gastaut syndrome (LGS): results of a multi-center, randomized, double-blind, placebo controlled trial (GWPCARE4)
    French, Jacqueline
    Thiele, Elizabeth
    Mazurkiewicz-Beldzinska, Maria
    Benbadis, Selim
    Marsh, Eric
    Joshi, Charuta
    Roberts, Claire
    Taylor, Adam
    Sommerville, Ken
    NEUROLOGY, 2017, 88
  • [48] Comment on “Cost-Effectiveness of Cannabidiol Adjunct Therapy Versus Usual Care for the Treatment of Seizures in Lennox-Gastaut Syndrome”
    Kelly Hollenack
    Jade Marshall
    PharmacoEconomics, 2021, 39 : 473 - 475
  • [49] Comment on "Cost-Effectiveness of Cannabidiol Adjunct Therapy Versus Usual Care for the Treatment of Seizures in Lennox-Gastaut Syndrome"
    Hollenack, Kelly
    Marshall, Jade
    PHARMACOECONOMICS, 2021, 39 (04) : 473 - 475
  • [50] ADDITION OF CANNABIDIOL TO CURRENT ANTIEPILEPTIC THERAPY REDUCES DROP SEIZURES IN CHILDREN AND ADULTS WITH TREATMENT - RESISTANT LENNOX-GASTAUT SYNDROME
    Ostrovsky, Daniel A.
    Ehrlich, Alan
    EXPLORE-THE JOURNAL OF SCIENCE AND HEALING, 2018, 14 (04) : 311 - 313